Which Covid Patients Get Monoclonals? CDC Study Spots Big Disparities.

White people had the best odds of receiving lifesaving antibody treatment.

A healthcare worker prepares an infusion for a patient at a drive-thru monoclonal antibody treatment in the parking lot of Wayne Health Detroit Mack Health Center in Detroit, Michigan, Dec. 23, 2021.Bloomberg/Getty

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.

At this point in the pandemic, it’s clear the coronavirus has taken a disproportionate toll on people of color. Black, Latino, and Native Americans have been more likely than white Americans to be infected, hospitalized, and ultimately die of Covid-19

But until now, it was unclear whether rates of treatment with drugs known to be at least somewhat effective—monoclonal antibodies, dexamethasone (a steroid), and the antiviral drug remdesivir—followed the same disparity trends. In a recent report from the Centers for Disease Control and Prevention, scientists analyzed data covering more than 800,000 patients across 41 health care systems from March 2020 to August 2021. And the results are concerning, especially for the monoclonals, which have been shown to help prevent hospitalizations in high-risk patients.

Overall, only a small number of patients each month—4 percent or less, on average—received monoclonal antibodies. But there were clear disparities as to who got them: On average, Black and Asian patients were treated with monoclonals 22 percent and 48 percent less often, respectively, than white patients. Other races, including Native Americans and Pacific Islanders, were treated 47 percent less often than white patients. Hispanic patients were treated with monoclonals 58 percent less often than those who were non-Hispanic. In fact, during nearly every month the researchers measured, white patients were more likely than the other groups to be given the potentially life-saving treatment. This chart sums it up:

Percentage of Covid patients who received monoclonal antibody treatment by race and ethnicity.

 CDC

The disparities for dexamethasone and remdesivir were “different and of lesser magnitude” the authors note, with Hispanic patients receiving dexamethasone 6 percent less often than non-Hispanic ones, and Black patients receiving remdesivir 9 percent more often than white patients.

The authors also cite limitations to the study, including that it was common for race and ethnicity data to be left off of records for people who tested positive, and that patient records were largely gathered from centers within the health care system, meaning they may not reflect trends among patients treated outside of those settings, such as government-run infusion sites.

The study suggests several possible reasons for the differences in monoclonal antibody treatment rates, including racial differences in access to transportation, testing, and care; “inadequate insurance coverage;” supply issues; “potential biases in prescribing practices;” and a lack of messaging in communities of color about the availability of the treatment.

Yet another possibility, as my colleague Edwin Rios aptly put it, is that, here in America, racism seems to be a preexisting condition.

We've never been very good at being conservative.

And usually, that serves us well in doing the ambitious, hard-hitting journalism that you turn to Mother Jones for. But it also means we can't afford to come up short when it comes to scratching together the funds it takes to keep our team firing on all cylinders, and the truth is, we finished our budgeting cycle on June 30 about $100,000 short of our online goal.

This is no time to come up short. It's time to fight like hell, as our namesake would tell us to do, for a democracy where minority rule cannot impose an extreme agenda, where facts matter, and where accountability has a chance at the polls and in the press. If you value our reporting and you can right now, please help us dig out of the $100,000 hole we're starting our new budgeting cycle in with an always-needed and always-appreciated donation today.

payment methods

We've never been very good at being conservative.

And usually, that serves us well in doing the ambitious, hard-hitting journalism that you turn to Mother Jones for. But it also means we can't afford to come up short when it comes to scratching together the funds it takes to keep our team firing on all cylinders, and the truth is, we finished our budgeting cycle on June 30 about $100,000 short of our online goal.

This is no time to come up short. It's time to fight like hell, as our namesake would tell us to do, for a democracy where minority rule cannot impose an extreme agenda, where facts matter, and where accountability has a chance at the polls and in the press. If you value our reporting and you can right now, please help us dig out of the $100,000 hole we're starting our new budgeting cycle in with an always-needed and always-appreciated donation today.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate